Five things for pharma marketers to know: Monday, April 17, 2017


1. Kim Kardashian West again posted promotional information on Instagram about Diclegis, Duchesnay's morning sickness drug. The first time she posted about the drug she failed to highlight the full risk information, which prompted the FDA to send a warning letter to Duchesnay. Kardashian also had to repost the ad, fully stating the risk information.

2. Drugmakers are trying new methods to bring non-opioid painkillers to market. They're looking closely at drugs like Enbrel, which treats one feature of rheumatoid arthritis and, as a result, eases pain and other therapies that prevent the need for opioids. (AP)

3. Healthcare organizations and brands, including Boehringer Ingelheim, GE Healthcare, and Tums, have started to experiment with Facebook Live. An analysis conducted by Unmetric found that more than half of the healthcare brand videos published last year were promoted. (Adweek)

4. The FDA declined to approve Olumiant, a new rheumatoid arthritis drug developed by Eli Lilly and Incyte. The agency said it needs more information about dosing and safety. (Reuters)

5. Companies that make organic and natural personal-care products are boosting their advertising spending in support of these products. (NYT)